J&J taps the bis­pe­cif­ic ex­perts at Xen­cor for prostate can­cer dis­cov­ery pact, kick­ing off with $50M up­front

J&J is try­ing some­thing new for prostate can­cer.

Team­ing up with Xen­cor, its Janssen sub­sidiary is look­ing to dis­cov­er bis­pe­cif­ic an­ti­bod­ies that grab CD28 on …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER